Biohaven Pharmaceutical Holding Company Ltd

NYSE:BHVN   12:59:59 PM EDT
113.81
-1.74 (-1.51%)
Strategic Combinations, Mergers / Acquisitions

Biohaven And Pfizer Enter Strategic Collaboration For Commercialization Of Rimegepant Outside United States

Published: 11/09/2021 12:53 GMT
Biohaven Pharmaceutical Holding Company Ltd (BHVN) - Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States.
Pfizer Inc - Biohaven to Receive Tiered Double-digit Royalties on Ex-u.s. Net Sales As Well As Upfront and Milestone Payments of Up to $1.24 Billion.
Pfizer Inc - Biohaven Would Remain Primarily Responsible for Further Clinical Development of Rimegepant.
Pfizer Inc - Parties Will Cooperate in Regulatory Activities to Secure Approval for Product.
Pfizer Inc - Pfizer Gains Rights Outside of U.S. to Zavegepant.
Pfizer Inc - Pfizer Will Make an Upfront Payment of $500 Million.
Pfizer Inc - Biohaven is Also Eligible to Receive Up to $740 Million in Milestones.
Pfizer Inc - Pfizer Will Make an Upfront Payment of $500 Million, Consisting of $150 Million Cash and $350 Million in Purchase of Biohaven Equity.